• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  lomitapide
Trade Name:  Juxtapid
Date Designated:  10/23/2007
Orphan Designation:  Treatment of homozygous familial hypercholesterolemia
Orphan Designation Status:  Designated/Approved
Marketing Approval Date:  12/21/2012 
Approved Labeled Indication:  Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Exclusivity End Date:    12/21/2019 
Exclusivity Protected Indication* :  
Aegerion Pharmaceuticals, Inc.
101 Main St., Suite 1850
Cambridge, Massachusetts 02142
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.